- Home
- NTRA vs AEE Comparison
NTRA vs AEE Comparison
Compare NTRA & AEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- AEE
- Stock Information
- Founded
- NTRA 2003
- AEE 1901
- Country
- NTRA United States
- AEE United States
- Employees
- NTRA N/A
- AEE N/A
- Industry
- NTRA Medical Specialities
- AEE Power Generation
- Sector
- NTRA Health Care
- AEE Utilities
- Exchange
- NTRA Nasdaq
- AEE Nasdaq
- Market Cap
- NTRA 20.6B
- AEE 18.7B
- IPO Year
- NTRA 2015
- AEE N/A
- Fundamental
- Price
- NTRA $164.72
- AEE $94.30
- Analyst Decision
- NTRA Strong Buy
- AEE Buy
- Analyst Count
- NTRA 17
- AEE 13
- Target Price
- NTRA $145.00
- AEE $85.36
- AVG Volume (30 Days)
- NTRA 1.5M
- AEE 1.6M
- Earning Date
- NTRA 11-12-2024
- AEE 11-06-2024
- Dividend Yield
- NTRA N/A
- AEE 2.85%
- EPS Growth
- NTRA N/A
- AEE N/A
- EPS
- NTRA N/A
- AEE 4.26
- Revenue
- NTRA $1,531,955,000.00
- AEE $7,058,000,000.00
- Revenue This Year
- NTRA $42.99
- AEE $5.22
- Revenue Next Year
- NTRA $13.31
- AEE $5.70
- P/E Ratio
- NTRA N/A
- AEE $22.06
- Revenue Growth
- NTRA 54.94
- AEE N/A
- 52 Week Low
- NTRA $53.62
- AEE $67.03
- 52 Week High
- NTRA $171.95
- AEE $93.99
- Technical
- Relative Strength Index (RSI)
- NTRA 74.09
- AEE 67.68
- Support Level
- NTRA $143.20
- AEE $89.54
- Resistance Level
- NTRA $167.79
- AEE $94.21
- Average True Range (ATR)
- NTRA 7.08
- AEE 1.87
- MACD
- NTRA 3.87
- AEE 0.40
- Stochastic Oscillator
- NTRA 94.92
- AEE 99.06
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves more than 2.4 million electricity customers and more than 900,000 natural gas customers.